Company

Zag Bio, Inc.

Zag Bio develops bifunctional antibody therapies that target the thymus to address autoimmune diseases.

About

Zag Bio develops therapies intended to induce immune tolerance by delivering self-antigens to specialized cells in the thymus. Its research focuses on autoimmune diseases, including Type 1 Diabetes. Founded in 2022 and based in Cambridge, US, the company raised USD 80 mn in Series A funding on October 28, 2025, with contributions from AbbVie Biotech Ventures and JDRF T1D Fund.

1Funding rounds

10Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in